CAI
Clinical Asset Index
by VOS Supply Group
Drugs · acquisition-cost intelligence

Diclofenac Potassium

diclofenac potassium· ingredient diclofenacAntiinflammatory agents, non-steroids· DICLOFENAC POTASSIUM 25 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$4.41
NADAC — pharmacy acquisition cost, not a retail/cash price

Acquisition-cost history

Weekly NADAC per EA — the trend nobody else shows. 9 weeks.

2025-12-172026-05-20

Same-ingredient options by acquisition cost

Other diclofenac products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.

ProductNADAC / EAvs this
Diclofenac Sodium Delayed Release$0.06665−$4.34
Diclofenac DR$0.06665−$4.34
Aleve Arthritis Pain Gel$0.08776−$4.32
Diclofenac Potassium$0.09863−$4.31
Clofenax$0.12486−$4.28
Diclofenac Sodium$0.36949−$4.04
Diclofenac Sodium$0.39681−$4.01
Diclofenac Sodium Delayed Release$0.72051−$3.69

Medicare Part D coverage · CY2026

On 1 plan formularies · typical tier 1
Prior auth 0% · Step therapy 0% · Quantity limit 0% of formularies

Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.